There has been increasing evidence to support aggressive therapeutic intervention in patients with early RA. A recent review addresses the need for early treatment, based on the concepts of tight control and the treat-to-target paradigm, leading to the ultimate goal of disease remission.
Gout affects joints via the accumulation of uric acid in the blood. The management of patients with gout is far from optimal, with only 33% to 50% of patients receiving urate-lowering therapy (ULT).
Rheumatoid arthritis (RA) often leads to work disability, early retirement, or self-perceived disability. The introduction of biologic agents, or anti–tumor necrosis factor (TNF)-alpha, has changed the outcomes for patients with RA by slowing disease progression and controlling disease activity.
Pharmacy cost now the key driver of RA expenditures By David Hawk The total incremental costs for the treatment of patients with rheumatoid arthritis (RA) in the United States accounted for $22.3 billion in 2008, according to a new cost analysis.
By Neil Canavan Berlin, Germany—A pair of economic studies presented at the 2012 European League Against Rheuma­tism Congress have analyzed work productivity losses among patients with rheumatoid arthritis (RA), as well as costs associated with sick leave and disability compensation in patients with RA.
By David Hawk Berlin, Germany—A multidisciplinary task force formed under the aegis of the European League Against Rheumatism (EULAR) has for the first time developed recommendations for the management of medium-to-high-dose systemic glucocorticoid therapy in rheumatic diseases.
Page 2 of 3
Results 11 - 20 of 29
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology